Radiobiology & cancer

Study on:
1. How high doses of radiotherapy (SBRT, IORT and HDR) could trigger immune stimulation through modulation of cytokines and immune cells in plasma.
2. Predictive radiation sensitivity tests.
3. New therapeutic strategies in brachytherapy.
4. New therapeutic strategies in external radiotherapy.
5. Evaluation of quality of life in the treatment of prostate cancer.
6. Application of intracranial stereotactic radiotherapy (SRT) and
7. Stereotactic body radiotherapy (SBRT) techniques.

• Guinot,JL;Gutierrez Miguelez,C;Meszaros,N;Gonzalez Perez,V;Santos,MA;Najjari,D;Slocker,A et al, Five-year results of the very accelerated partial breast irradiation VAPBI phase I-II GEC-ESTRO trial, Radiother. Oncol., 2024;201doi:10.1016/j.radonc.2024.110543
• Hannoun Levi,JM;Morales,MG;Gal,J;Anchuelo,J;Guinot,JL;Gaztañaga,M;Meszaros,N et al, Very accelerated partial breast irradiation in 1 or 2 days: Late toxicity and early oncological outcome of the GEC-ESTRO VAPBI cohort, Radiother. Oncol., 2024;194doi:10.1016/j.radonc.2024.110217
• De Brabandere,M;Placidi,E;Siebert,FA;Tedgren,AC;Escarpa,AS;Tagliaferri,L;Andr,M et al, GEC-ESTRO survey of 106Ru eye applicator practice for ocular melanoma – Physicist survey, Radiother. Oncol., 2024;193doi:10.1016/j.radonc.2024.110114
• Conde Moreno,AJ;López Campos,F;Hervás,A;Morillo,V;Méndez,A;Puertas,MDM;Valero Albarrán,J et al, A Phase II Trial of Stereotactic Body Radiation Therapy and Androgen Deprivation for Oligometastases in Prostate Cancer (SBRT-SG 05), Pract. Radiat. Oncol., 2024;14(5):doi:10.1016/j.prro.2024.04.022
• González San Segundo,C;Campos,FL;Iturriaga,AG;Rodríguez,A;Olivera,J;Duque Santana,V;Sancho,G et al, A randomised trial of short- vs long-term androgen deprivation with salvage radiotherapy for biochemical failure following radical prostatectomy: URONCOR 06-24, BJU Int., 2024;134(4):568-577, doi:10.1111/bju.16484

• 2015-003007-38. ESTUDIO DE FASE 3 ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO DE JNJ-56021927 EN SUJETOS CON CÁNCER DE PRÓSTATA LOCALIZADO O LOCALMENTE AVANZADO Y DE ALTO RIESGO QUE ESTÁN RECIBIENDO TRATAMIENTO CON RADIOTERAPIA PRIMARIA. Janssen-Cilag, S.A. Budget: 55.750€. 2016- . PI: Boladeras Inglada, Ana Mª.
• BAY-DAR-2021-01. DAROL: ESTUDIO OBSERVACIONAL DE DAROLUTAMIDA EN PACIENTES CON CÁNCER DE PRÓSTATA RESISTENTE A LA CASTRACIÓN NO METASTÁSICO. Bayer AG. Budget: 8.500€. 2022- . PI: Ferrer González, Ferran.
• RET-LB. ESTUDIO DE SEGUNDOS CÁNCERES EN PACIENTES CON RETINOBLASTOMA HEREDITARIO; DISEÑO DE UNA ESTRATEGIA BASADA EN BIOPSIA LÍQUIDA PARA UN DIAGNÓSTICO PRECOZ Y UN SEGUIMIENTO ADECUADO (RET-LB PROJECT). FUNDACIO LA NINETA DELS ULLS. 2024- . PI: Gutiérrez Miguélez, Cristina.
• 2023-439-1. RETROSPECTIVE CERVICAL CANCER OLIGO STATES (RECURRENCE, METASTASIS) MULTICENTRE OUTCOMES STUDY (RETRO-COSMOS). EMBRACE Research Group. 2024- . PI: Najjari Jamal, Dina.
• 2023-543-1. ESTUDIO OBSERVACIONAL RETROSPECTIVO MULTICÉNTRICO: TRATAMIENTO DE RECAÍDA LOCAL CON BRAQUITERAPIA DE RESCATE DE PRÓSTATA. DETERMINACIÓN DE TÉCNICA Y FRACCIONAMIENTO DE DOSIS, EFECTO PET COLINA EN DIAGNÓSTICO PRECOZ Y SU EFECTO EN SUPERVIVENCIA.. iInstituto de Investigación en Oncología Radioterápica FEOR-IR. 2023- . PI: SLOCKER ESCARPA, ANDREA.

We currently have three industry-funded projects under way:

Immune modulation through brachytherapy in blood and tumour microenvironment.
Detection of systemic immune response to peripheral blood provided by high doses of radiation given to the lung in stereotactic conditions.
INTRABEAM: precision hypofractionated radiotherapy with immune-system response.
Over the past five years, we have obtained two competitive projects, Healthcare Research and Development Strategy grants:
Long-term effectiveness: 10-year follow-up of the “Spanish Multicentre Study of Localised Prostate Cancer” cohort (PI13 / 00412).
Efficacy of new treatments for low-risk localised prostate cancer: a randomised clinical trial (PI13 / 00412).